View Cover
The expanding array of new antineoplastic agents offer better options for cancer patients, but with class-specific side effects.
By Kapil Mishra, MD, Rolando Sceptre Ganasi, BS
A case series highlights the clinical versatility of this VEGF-A and Ang2 inhibitor in a real-world setting, beyond the limits of clinical trials.
By Lauren Pickel, BS, Nirojini Sivachandran, MD, PhD, FRCSC
Although CME successfully resolved after the drug was discontinued, this rare case suggests potential ocular risks with S1P receptor modulators.
By Jeffrey Bloom, DO, Caleb Liles, DO, Jacob Brucker, DO, et al.
Retina doctors and their families enjoyed the fourth national meeting of the American Retina Forum, held August 7 to 10 in Carlsbad, California.
By Mitul Mehta, MD, MS, FASRS
When pushback is encountered, acknowledging shared fears can encourage open-mindedness and acceptance of innovation.
By Elizabeth Cifers, MBA, MSW, CHC, CPC
